Health Care [ 9/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.
The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 24 | -0.27 Increased by +32.50% | -0.41 Increased by +34.15% |
| Aug 9, 24 | -0.45 Decreased by -15.38% | -0.42 Decreased by -7.14% |
| May 15, 24 | -0.86 Increased by +18.10% | -0.14 Decreased by -514.29% |
| Feb 28, 24 | -1.54 Decreased by -50.98% | -0.16 Decreased by -862.50% |
| Oct 13, 23 | -0.40 Increased by +71.43% | - |
| Aug 11, 23 | -0.39 Increased by +78.33% | -0.52 Increased by +25.00% |
| May 8, 23 | -1.05 Increased by +41.67% | -0.86 Decreased by -22.09% |
| Mar 20, 23 | -1.02 Increased by +36.25% | -1.34 Increased by +23.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -5.85 M Decreased by -220.03% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.94 M Decreased by -400.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 134.00 K Increased by +N/A% | -7.11 M Decreased by -56.43% | Decreased by -5.31 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -7.34 M Decreased by -67.14% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.83 M Increased by +70.79% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.79 M Increased by +77.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.55 M Increased by +46.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -4.39 M Increased by +35.42% | Decreased by N/A% Decreased by N/A% |